+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Allogeneic Cell Therapy Market by Type (Chimeric Antigen Receptor T Cell Therapy, Hematopoietic Stem Cell Transplantation, Induced Pluripotent Stem Cell Therapy), Application (Hematological Disorders, Oncology, Regenerative Medicine), End-Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967517
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allogeneic Cell Therapy Market grew from USD 2.04 billion in 2023 to USD 2.31 billion in 2024. It is expected to continue growing at a CAGR of 13.90%, reaching USD 5.08 billion by 2030.

Ongoing advances in genetic engineering, cell processing, and culturing techniques have significantly enhanced the efficacy and safety of allogeneic cell therapies, fueling market growth. The growing incidence of cancers, autoimmune diseases, and cardiovascular conditions globally drives the demand for innovative treatments such as allogeneic cell therapy. Favorable government policies worldwide and increased funding for research in cell-based therapies have accelerated market expansion. However, high costs associated with the development and administration of allogeneic cell therapies limit accessibility for a broader patient base. Immune rejection and the need for immunosuppressants to avoid adverse reactions remain significant challenges for market growth. Moreover, continuous research aiming at improving cell sourcing, preservation, and scalability presents substantial opportunities for market growth. Developing tailored allogeneic cell therapy solutions catering to individual patient profiles may open new avenues for personalized medicine.

Regional Insights

The Americas, particularly the United States and Canada, are at the forefront of the allogeneic cell therapy industry, driven by robust investments, cutting-edge research, and a supportive regulatory environment that is increasingly conducive to innovation in biotechnology. Intellectual property developments, typified by a steady stream of patents related to cell processing techniques and bioreactor designs, demonstrate the vibrancy of the market in the Americas region. The European Union observes strong government and private support for regenerative medicine, including allogeneic cell therapy. Countries such as Germany, the United Kingdom, and France have been particularly active, with numerous clinical trials and research initiatives, and also benefit from a regulatory framework encouraging innovation while ensuring patient safety. Middle East countries such as the United Arab Emirates and Saudi Arabia, are investing significantly in healthcare infrastructure and have shown interest in adopting advanced medical treatments, including cell therapies. The African region is more diverse, with South Africa leading in terms of research and interest in regenerative medicine. In the APAC region, China has made remarkable strides, with substantial government backing for biotechnology research. Japan and India have a well-established reputation for pioneering regenerative medicine, supported by favorable regulatory policies to fast-track promising therapies.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Allogeneic Cell Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
  • Favorable government policies and increased funding for research in cell-based therapies

Market Restraints

  • Complex regulatory environment for development and administration of allogeneic cell therapies

Market Opportunities

  • Development of personalized allogeneic cell therapy solutions
  • Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases

Market Challenges

  • Immune rejection and compatibility issues

Market Segmentation Analysis

  • Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
  • Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Allogeneic Cell Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Allogeneic Cell Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing

Getinge has partnered with bioprocessing innovator CellRev to create a groundbreaking continuous cell processing platform named Livit ACE, aimed at transforming the manufacturing landscape of allogeneic cell therapies. This partnership synergizes CellRev's cutting-edge technology with Getinge's advanced bioreactor systems, potentially accelerating the development of vital therapies.

StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies

In a significant development for the rapidly expanding field of cell therapy, StemCyte has entered a cooperative agreement, specializing in the development of allogeneic genetically modified CAR-NK cells derived from umbilical cord blood. This agreement positions StemCyte as the primary supplier of cellular materials essential for allogeneic cell therapy products worldwide, heralding a new era in making cell therapies more accessible and feasible as a standard treatment option.

FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment

In a landmark development, Gamida Cell Ltd. has received FDA approval for Omisirge (omidubicel-onlv), designed for patients aged 12 and older with hematologic malignancies, undergoing umbilical cord blood transplantation post-myeloablative conditioning. This therapy offers a vital, potentially life-saving option for treating various hematologic malignancies, heralding a new era in healthcare equity and patient care.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Allogeneic Cell Therapy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

  • Chimeric Antigen Receptor T Cell Therapy
  • Hematopoietic Stem Cell Transplantation
  • Induced Pluripotent Stem Cell Therapy
  • Mesenchymal Stem Cell Therapy

Application

  • Hematological Disorders
  • Oncology
  • Regenerative Medicine
  • Solid Organ Transplantation

End-Use

  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics
  • Research Institutes

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
5.1.2. Restraints
5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
5.1.3. Opportunities
5.1.3.1. Development of personalized allogeneic cell therapy solutions
5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
5.1.4. Challenges
5.1.4.1. Immune rejection and compatibility issues
5.2. Market Segmentation Analysis
5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Allogeneic Cell Therapy Market, by Type
6.1. Introduction
6.2. Chimeric Antigen Receptor T Cell Therapy
6.3. Hematopoietic Stem Cell Transplantation
6.4. Induced Pluripotent Stem Cell Therapy
6.5. Mesenchymal Stem Cell Therapy
7. Allogeneic Cell Therapy Market, by Application
7.1. Introduction
7.2. Hematological Disorders
7.3. Oncology
7.4. Regenerative Medicine
7.5. Solid Organ Transplantation
8. Allogeneic Cell Therapy Market, by End-Use
8.1. Introduction
8.2. Biotechnology & Pharmaceutical Companies
8.3. Hospitals & Clinics
8.4. Research Institutes
9. Americas Allogeneic Cell Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Allogeneic Cell Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Allogeneic Cell Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 51. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 52. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 55. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 56. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 57. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 58. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 59. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 60. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 61. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 62. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 63. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 64. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 65. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 66. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 71. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 72. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 73. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 74. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 80. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 82. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 85. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 86. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 87. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 88. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 89. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 90. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 91. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 92. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 93. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 94. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 95. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 96. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 97. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 100. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 103. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 104. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 105. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 106. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 107. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 108. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 109. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 110. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 111. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 112. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 115. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 118. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 121. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 122. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 123. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 124. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 127. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 128. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 129. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 130. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 133. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 134. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 135. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 136. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 139. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 142. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 143. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 144. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 145. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 146. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 147. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 148. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 151. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 152. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 153. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 154. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 163. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 164. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 165. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 166. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 167. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 168. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 169. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 170. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 171. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 172. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 173. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 174. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 175. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 176. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 177. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 178. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 179. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 180. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 181. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 182. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 183. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 184. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 185. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 186. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 187. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 188. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 189. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 190. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 191. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 192. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 195. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 196. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 197. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 198. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 199. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 200. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 201. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 202. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 203. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 204. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 208. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 209. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 210. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 213. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 214. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 215. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 216. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 217. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 218. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 219. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 220. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 221. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 222. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 223. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 224. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 225. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 226. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 227. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 228. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 229. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 230. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 231. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 234. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 237. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 238. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 239. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 240. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 244. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 246. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 250. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 252. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 253. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 254. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 255. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 256. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 257. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 258. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 261. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 262. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 263. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 264. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 267. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 268. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 269. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 270. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 271. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 272. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 273. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 274. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 275. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 276. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 286. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 288. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 289. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 290. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abeona Therapeutics Inc.
  • AlloSource
  • Anterogen.Co., Ltd.
  • Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • Athersys Inc.
  • Biorestorative Therapies Inc.
  • Biosolution Co., Ltd.
  • Bloodworks Northwest
  • Brainstorm Cell Limited
  • Caribou Biosciences
  • Fate Therapeutics
  • Gamida Cell
  • Hope Biosciences
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • MEDIPOST Co., Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc. by Globus Medical
  • RTI Surgical
  • Smith+Nephew PLC
  • Stempeutics Research Pvt. Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tego Science Inc.
  • ViaCyte Inc. by Vertex Pharmaceuticals

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.08 Billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal

Related Topics

Related Reports

Global Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Forecast 2024-2030 - Product Image

Global Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Allogeneic T-cell therapy for autoimmune diseases - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Allogeneic T-cell therapy for autoimmune diseases - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Allogeneic Cell Therapy Global Market Report 2024 - Product Image

Allogeneic Cell Therapy Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Global Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • Report
  • 110 Pages
  • Global
From
Allogeneic Cell Therapies - Pipeline Insight, 2024 - Product Image

Allogeneic Cell Therapies - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Allogeneic Cell Therapy Market

Allogeneic cell therapy is a type of genomics-based therapy that uses cells from a donor to treat a patient. It is a form of immunotherapy that uses cells from a healthy donor to stimulate the patient's immune system to fight disease. Allogeneic cell therapy is used to treat a variety of conditions, including cancer, autoimmune diseases, and genetic disorders. It is also being explored as a potential treatment for neurological disorders. Allogeneic cell therapy is a rapidly growing field, with many companies developing new treatments and technologies. Examples of companies in the allogeneic cell therapy market include Kite Pharma, Juno Therapeutics, and Bellicum Pharmaceuticals. Other companies, such as Cellectis and Fate Therapeutics, are also researching and developing allogeneic cell therapies. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.